New Cancer Drug Target in Dual-Function Protein
News Jun 29, 2016
The new findings, published June 27, 2016 in the journal Nature Structural & Molecular Biology, suggest that future therapies might target this protein, called GlyRS, to halt cancer growth.
“We have potentially found an important target for anti-cancer treatment,” said TSRI Professor Xiang-Lei Yang, who led the study.
Catching a Double Agent
Since the early days of life on Earth, GlyRS has played a role in protein synthesis, helping cells function and grow.
The new study, a collaboration with Professor Patrick Griffin’s lab on the Florida campus of TSRI, reveals that GlyRS is actually a double agent—in addition to its biologically essential role in making proteins, it can help to further modify proteins in a way that launches cancer growth.
The researchers found that overexpression of GlyRS may lead to too little p27—a protein than Yang compared to a stop sign for cell growth.
Specifically, the team found that GlyRS creates a protective shield around a modifier protein, called NEDD8, and safely “chaperones” it to meet its target protein, called cullin. With NEDD8 in place, cullin is activated to degrade p27.
Kept at the right levels, p27 regulates the cell cycle, stopping potential cancer growth. But when GlyRS levels increase, too much p27 gets degraded and cells multiply unchecked.
“Cancer cells hijack and over-exaggerate the system,” said TSRI Research Associate Zhongying Mo, first author of the study. “This can lead to tumorigenesis.”
This process is especially dangerous given GlyRS’s additional function in protein synthesis, which supplies cancers with the proteins they need to keep growing. “Ultimately, both functions are linked to cell proliferation and tumorigenesis,” Yang said.
Indeed, when Mo analyzed data from a breast cancer tissue database, she found that patients with increased GlyRS had higher mortality.
Although this research is at the basic stage, the team believes it could guide future cancer diagnostics and therapies. For example, measuring GlyRS may provide a marker to help doctors predict how quickly a patient’s cancer might progress.
The team now plans to study the effects of GlyRS in different types of cancer and the possibility of developing a drug to inhibit GlyRS.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE